KLP Kapitalforvaltning AS Buys Shares of 19,300 10x Genomics, Inc. (NASDAQ:TXG)

KLP Kapitalforvaltning AS purchased a new position in 10x Genomics, Inc. (NASDAQ:TXG) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 19,300 shares of the company’s stock, valued at approximately $277,000.

Other large investors have also recently made changes to their positions in the company. Signaturefd LLC raised its holdings in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after acquiring an additional 1,452 shares during the last quarter. Blue Trust Inc. grew its position in shares of 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after purchasing an additional 1,299 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in 10x Genomics during the fourth quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. boosted its stake in 10x Genomics by 817.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock worth $70,000 after buying an additional 4,324 shares during the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Mateo bought 40,000 shares of 10x Genomics stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the acquisition, the director now owns 61,691 shares of the company’s stock, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.03% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on TXG shares. Stifel Nicolaus cut their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. UBS Group reduced their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, March 22nd. Finally, Canaccord Genuity Group decreased their price objective on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.21.

10x Genomics Trading Down 6.3 %

TXG stock opened at $7.47 on Monday. The business’s fifty day moving average price is $11.41 and its 200 day moving average price is $14.56. 10x Genomics, Inc. has a 12-month low of $7.19 and a 12-month high of $37.74. The company has a market capitalization of $913.60 million, a PE ratio of -4.91 and a beta of 2.01.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.